Resistance of prostate cancer cell lines to COX-2 inhibitor treatment

Matthew Wagner, James Loos, Nicole Weksler, Marin Gantner, Christopher L. Corless, John M. Barry, Tomasz M. Beer, Mark Garzotto

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Targeting of cyclooxygenase-2 (COX-2) for cancer chemoprevention is well supported for several tumor types, most notably colon cancer. In contrast, the data for its role in prostate cancer carcinogenesis are correlative only. Thus, we compared the COX-2 expression, activity, and effects of inhibition in prostate cancer cells on COX-2-dependent colon cancer cells. COX-2 levels in benign and malignant human prostate tissue were determined by immunohistochemistry. Compared to colon cancer cells, prostate cancer cells expressed lower levels of COX-2, produced less PGE2, and were resistant to selective COX-2 inhibition. Examination of benign prostatic epithelium from prostatectomy samples demonstrated rare foci of COX-2. Whereas, human prostate cancer sections were uniformly negative for COX-2. In conclusion, these studies indicate the lack of a putative role for COX-2 in prostate cancer development. Direct evidence for the involvement of COX-2 in prostate cancer carcinogenesis is desperately needed.

Original languageEnglish (US)
Pages (from-to)800-807
Number of pages8
JournalBiochemical and Biophysical Research Communications
Issue number3
StatePublished - Jul 8 2005


  • Apoptosis
  • COX-2
  • Chemoprevention
  • LNCaP
  • Prostaglandin E2
  • Prostate cancer

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Resistance of prostate cancer cell lines to COX-2 inhibitor treatment'. Together they form a unique fingerprint.

Cite this